Literature DB >> 35301751

Increased serum pro-B-type natriuretic peptide in hematopoietic progenitor cell donors stimulated with G-CSF.

Leonard N Chen1, Celina Montemayor-Garcia2, Kamille A West-Mitchell1, Cathy C Cantilena1.   

Abstract

Hematopoietic stem cells (HPCs) donors mobilized by granulocyte-colony-stimulating factor (G-CSF) can develop various signs and symptoms. proBNP (pro-B-type natriuretic peptide) is a serum marker of heart failure. A donor who developed severe adverse reactions after G-CSF mobilization was found to have high serum proBNP levels. We followed additional donors who received identical mobilization regimen to investigate the prevalence of this phenomenon. Eighteen healthy donors underwent a mobilization regimen of 10 μg/Kg G-CSF daily for 5 days prior to allogeneic HPC collection using Spectra Optia between January 2016 and February 2017 were included in this study. Serum proBNP levels were measured before and after G-CSF stimulation and immediately after apheresis. Apheresis collection parameters and other laboratory results were also reviewed. The majority of donors (86.7%) had post-G-CSF elevation of serum proBNP. Seven of those had elevated proBNP above upper normal range (124 pg/ml). The subgroup of donors with normal proBNP is younger (median age of 37 vs 42 years), with majority being male (90.9% vs 28.6%) and with smaller processed blood volume (2.2 vs 3 × total blood volume). This case series demonstrates an increase of serum proBNP can be common in HPC donors stimulated with 5 days of 10 mcg/kg G-CSF. This is an adverse reaction that has not been described before. The temporary elevation of proBNP in these donors is not associated with ventricular dysfunction of the heart. The risk factors for marked elevation of proBNP post-G-CSF should be further investigated.
© 2022 Wiley Periodicals LLC. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  G-CSF; apheresis; hematopoietic progenitor cells; hematopoietic stem cell transplantation; pro B-type natriuretic peptide

Mesh:

Substances:

Year:  2022        PMID: 35301751      PMCID: PMC9378357          DOI: 10.1002/jca.21979

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.605


  25 in total

1.  Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection.

Authors:  M K Froberg; U C Garg; D F Stroncek; M Geis; J McCullough; D M Brown
Journal:  Transfusion       Date:  1999-04       Impact factor: 3.157

Review 2.  Brain natriuretic peptide: a biomarker for all cardiac disease?

Authors:  Gnanadevan Mahadavan; Thanh H Nguyen; John D Horowitz
Journal:  Curr Opin Cardiol       Date:  2014-03       Impact factor: 2.161

3.  Comparison of different low density lipoprotein apheresis machines on brain natriuretic Peptide levels in patients with familial hypercholesterolemia.

Authors:  Patrick Moriarty; Rachel Sosland; Cheryl Gibson; John Belmont
Journal:  Ther Apher Dial       Date:  2010-02       Impact factor: 1.762

Review 4.  G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent.

Authors:  Linda J Bendall; Kenneth F Bradstock
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-23       Impact factor: 7.638

Review 5.  Cutting Edge of Brain Natriuretic Peptide (BNP) Research - The Diversity of BNP Immunoreactivity and Its Clinical Relevance.

Authors:  Koichiro Kuwahara; Yasuaki Nakagawa; Toshio Nishikimi
Journal:  Circ J       Date:  2018-08-21       Impact factor: 2.993

6.  Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Bronwen E Shaw; John R Wingard; Hillard M Lazarus; Edmund K Waller; Matthew Seftel; David F Stroncek; Angela M Lopez; Dipnarine Maharaj; Peiman Hematti; Paul V O'Donnell; Alison W Loren; Susan F Leitman; Paolo Anderlini; Steven C Goldstein; John E Levine; Willis H Navarro; John P Miller; Dennis L Confer
Journal:  Blood       Date:  2012-10-29       Impact factor: 22.113

7.  Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; Brent R Logan; Willis H Navarro; John E Levine; John P Miller; Bronwen E Shaw; Paul V O'Donnell; Navneet S Majhail; Dennis L Confer
Journal:  Blood       Date:  2014-04-15       Impact factor: 22.113

8.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; John P Miller; Brent R Logan; Roberta J King; J Douglas Rizzo; Susan F Leitman; Paolo Anderlini; Michael D Haagenson; Seira Kurian; John P Klein; Mary M Horowitz; Dennis L Confer
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

9.  Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.

Authors:  Israel Henig; Tsila Zuckerman
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

10.  Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors-Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses.

Authors:  Tor Henrik Anderson Tvedt; Guro K Melve; Galina Tsykunova; Aymen Bushra Ahmed; Annette K Brenner; Øystein Bruserud
Journal:  Int J Mol Sci       Date:  2018-09-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.